About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

LGSOC is a rare ovarian cancer often affecting younger women, with no FDA-approved treatments

Approximately 80% of people treated for LGSOC will have their cancer come back

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, and the STAAR Ovarian Cancer Foundation today announced the first Low-Grade Serous Ovarian Cancer Awareness Day or “LGSOC Awareness Day” on September 9, 2024.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903051307/en/

September is Ovarian Cancer Awareness Month and LGSOC is a rare ovarian cancer with little information and awareness available to patients and caregivers. This newly created annual LGSOC Awareness Day will educate people about the symptoms of LGSOC, provide resources to people diagnosed with LGSOC, and advocate for more research.

“When I was diagnosed with LGSOC I knew nothing about this rare ovarian cancer and found that very little information existed about the disease. It is one of my goals to ensure that the first-ever LGSOC Awareness Day will bring much-needed awareness and attention to this rare ovarian cancer so that no person diagnosed with this disease feels alone,” said Nicole Andrews, Board of Directors Chair, STAAR Ovarian Cancer Foundation. “Currently, there are limited treatment options available for LGSOC and no FDA-approved treatments specifically for LGSOC. As the first U.S. foundation dedicated to funding LGSOC research, we want to do more to elevate the unmet needs for this disease and give patients living with LGSOC a voice in the ovarian cancer conversation.”

To help raise awareness and participate in the first LGSOC Awareness Day on Monday, September 9:

“The inaugural LGSOC Awareness Day builds on the recognition of LGSOC as a distinct disease that is different from other ovarian cancers,” said Dan Paterson, president and chief executive officer of Verastem Oncology. “At Verastem, we are committed to understanding LGSOC from both a disease and patient perspective. We are conducting clinical trials for an investigational treatment combination for LGSOC and have initiated a rolling new drug application with the FDA to potentially bring the first treatment to patients specifically approved for LGSOC. We will continue to do our part to raise awareness about LGSOC with STAAR and the entire LGSOC community while also working to improve outcomes for those living with LGSOC and their families.”

The first-ever LGSOC Patient Impact Survey, conducted in 2023, revealed particular challenges with diagnosis, disease management, and mental, physical, and emotional well-being for people living with LGSOC. Nearly all those surveyed (99%) had no awareness of LGSOC prior to diagnosis, and 60% did not feel that their HCP was “very knowledgeable” about this rare cancer.

This newly formed awareness day is set during Ovarian Cancer Awareness Month to bring a focus to low-grade serous ovarian cancer.

About Low-Grade Serous Ovarian Cancer

Low-grade serous ovarian cancer (LGSOC) is a highly recurrent, chemotherapy-resistant cancer, associated with slow tumor growth and high mortality rate. Approximately 6,000-8,000 women in the U.S. and 80,000 worldwide are living with this disease. LGSOC is most often diagnosed in women between the ages of 45-55 and affects a younger patient population with bimodal peaks at ages 20-30 and 50-60 years of age and has a median survival of approximately ten years. The majority of patients experience severe pain and complications as the disease progresses. Approximately, 80% of people with LGSOC have their cancer come back after remission. While chemotherapy is the standard of care for this disease, there are no treatments specifically approved by the U.S. Food and Drug Administration to treat LGSOC and limited other treatment options are available.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on RAS/MAPK-driven cancers, specifically novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.

About STAAR Ovarian Cancer Foundation

STAAR Ovarian Cancer Foundation is the first charity created in the United States dedicated to funding research into effective treatments for low-grade serous ovarian cancer and improving outcomes for the people diagnosed with it. It was founded in 2020 by three women with LGSOC and is run by a board of volunteers, half of whom are living with the disease. Since its founding, it has contributed more than $600,000 toward LGSOC research at leading institutions.

Contacts

For Inquiries:

Julissa Viana

Vice President, Corporate Communications and Investor Relations

media@verastem.com

Kari Neumeyer, Vice Chair, Marketing & Communications

karineumeyer@gmail.com

Ph: 360-510-9396

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.